相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials
Robin Christensen et al.
LANCET (2007)
Mechanisms linking obesity with cardiovascular disease
Luc F. Van Gaal et al.
NATURE (2006)
Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study
Andre J. Scheen et al.
LANCET (2006)
Regulation, function, and dysregulation of endocannabinoids in models of adipose and β-pancreatic cells and in obesity and hyperglycemia
Isabel Matias et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2006)
Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients - RIO-North America: A randomized controlled trial
F Pi-Sunyer et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2006)
Obesity and cardiovascular disease: Pathophysiology, evaluation, and effect of weight loss - An update of the 1997 American Heart Association Scientific Statement on obesity and heart disease from the Obesity Committee of the Council on Nutrition, Physical Activity, and Metabolism
P Poirier et al.
CIRCULATION (2006)
Cannabinoid receptors regulate Ca2+ signals and insulin secretion in pancreatic β-cell
P Juan-Picó et al.
CELL CALCIUM (2006)
The endocannabinoid system in the physiology and pathophysiology of the gastrointestinal tract
F Massa et al.
JOURNAL OF MOLECULAR MEDICINE-JMM (2005)
Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia
JP Despres et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Activation of the peripheral endocannabinoid system in human obesity
S Engeli et al.
DIABETES (2005)
Overweight and obesity associated with a missense polymorphism in fatty acid amide hydrolase (FAAH)
JC Sipe et al.
INTERNATIONAL JOURNAL OF OBESITY (2005)
Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity
D Osei-Hyiaman et al.
JOURNAL OF CLINICAL INVESTIGATION (2005)
Endocannabinoid control of food intake and energy balance
V Di Marzo et al.
NATURE NEUROSCIENCE (2005)
Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients:: 1-year experience from the RIO-Europe study
LF Van Gaal et al.
LANCET (2005)
Effects of the cannabinoid CB1 receptor antagonist SR141716 on oxygen consumption and soleus muscle glucose uptake in Lepob/Lepob mice
YL Liu et al.
INTERNATIONAL JOURNAL OF OBESITY (2005)
Diabetes, prediabetes, and cardiovascular risk: Shifting the paradigm
PC Deedwania et al.
AMERICAN JOURNAL OF MEDICINE (2005)
Clinical implications of obesity with specific focus on cardiovascular disease - A statement for professionals from the American Heart Association Council on Nutrition, Physical Activity, and Metabolism - Endorsed by the American College of Cardiology Foundation
S Klein et al.
CIRCULATION (2004)
The cannabinoid CB1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells
M Bensaid et al.
MOLECULAR PHARMACOLOGY (2003)
Anti-obesity effect of SR141716, a CB1 receptor antagonist, in diet-induced obese mice
CR Trillou et al.
AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY (2003)
Weight-loss maintenance in overweight individuals one to five years following successful completion of a commercial weight loss program
MR Lowe et al.
INTERNATIONAL JOURNAL OF OBESITY (2001)
分享论文
